In search of new cytomegalovirus vaccine antigens

Project Information

MEGALOVAX

Grant agreement ID: 253507

Project closed

Start date 1 July 2010

End date 30 June 2012

Funded under

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Total cost € 164 958,60

EU contribution € 164 958,60

Coordinated by

GLAXOSMITHKLINE VACCINES SRL
Italy

Objective

Aim of the project is to search for antigens that induce neutralizing antibodies in mice, which prevent entry of Human cytomegalovirus (HCMV) in vitro, and to characterize the identified candidate antigen with respect to its function. We will employ the “reverse vaccinology approach” with two robust technological platforms. A published genomic DNA sequence of HCMV has been analyzed and identified putative genes encoding surface exposed or secreted proteins using computer algorithms. Based on this analysis, candidate DNA sequences have been synthesized and are ready for cloning into expression vectors. •The selected genes will be expressed in eukaryotic cells in vitro and characterized to compare with information obtained from the bioinformatic analyses. •To screen immunogenicity of the candidate proteins, we will insert candidate genes into alphavirus vector to prepare pseudo-virion (alphavirus replicon particles), which induce robust immune responses in mice against the expressed gene product. Sera from immunized mice will be collected and submitted to immunological assays, including western blotting, immunofluorescence studies and in vitro neutralization assays. •In vitro neutralization assays will be set up with bacterial artificial chromosome (BAC) system that produce recombinant HCMV expressing a reporter gene to detect infection to cultured cells. •Sera from HCMV seropositive individuals will be analyzed to detect existence of specific antibodies to selected antigens by western blotting or the protein microarray technology. Screening of vaccine targets against HCMV infection in MEGALOVAX includes the reverse vaccinology approach applied for the first time to viral pathogens with the two abovementioned technological platforms. This new approach is expected to offer a breakthrough of discovery of new HCMV antigens for protection. The results from this project will also contribute to further understanding of viral-host interactions during HCMV infection.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• medical and health sciences › medical biotechnology
• natural sciences › biological sciences › microbiology › virology
• natural sciences › biological sciences › genetics › DNA
• natural sciences › biological sciences › biochemistry › biomolecules › proteins

You need to log in or register to use this function

Programme(s)

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Topic(s)

• FP7-PEOPLE-2009-IEF - Marie Curie Action: "Intra-European Fellowships for Career Development"

Call for proposal

FP7-PEOPLE-2009-IEF
See other projects for this call

Funding Scheme

MC-IEF - Intra-European Fellowships (IEF)

Coordinator

GLAXOSMITHKLINE VACCINES SRL

• EU contribution: € 164 958,60
• Address: VIA FIORENTINA 1 ; 53100 Siena ; Italy
• Region: Centro (IT) › Toscana › Siena
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: No data